SALT LAKE CITY, July 9, 2024 /PRNewswire/ --DiscGenics, Inc., a privately held, late-stage clinical, biopharmaceutical company developing allogeneic, cell-based, regenerative therapies for musculoskeletal degeneration, today announced publication of results in the International Journal of Spine Surgery from the combined Phase I/Phase II, first-in-human clinical study of an allogeneic disc progenitor cell therapy (IDCT or rebonuputemcel) for painful lumbar degenerative disc disease (DDD).
The study met the primary safety and efficacy endpoints, showing that a single intradiscal injection of high-dose IDCT (9,000,000 cells/mL) safely increases disc volume and produces statistically significant, clinically meaningful improvements in back pain, disability, and quality of life out to 2 years post-injection in patients with lumbar disc degeneration.
"The results from this study demonstrate IDCT's potential to safely and effectively reduce pain associated with DDD while also producing a regenerative effect within the degenerating disc. MRI image analysis of disc volume indicated the potential to halt and possibly reverse the progression of the disease," said Matthew F. Gornet, M.D., lead author, Board Certified Spine Surgeon at The Orthopedic Center of St. Louis, and top enroller in the IDCT study. "I have been a practicing spine surgeon for more than 30 years and been involved in over 35 FDA clinical trials, and the patient outcomes from this study are very promising."
In the FDA-allowed, prospective, randomized, double-blinded, vehicle- and placebo-controlled,multicenter study, 60 patients with symptomatic, single-level lumbar DDD were randomized to receive single intradiscal injections of either low-dose cells (n= 20), high-dose cells (n= 20), vehicle alone (n= 10), or placebo (n= 10). The primary endpoint was mean visual analog scale (VAS) pain improvement >30% at 52 weeks. Disability and quality of life were evaluated via Oswestry Disability Index (ODI) and EQ-5D, respectively. Disc volume was radiologically assessed. Adverse events (AEs), regardless of whether they were related to treatment, were reported. Patients were assessed at baseline and at 4, 12, 26, 52, 78, and 104 weeks post treatment.
At Week 52, the primary study period, the high-dose group had a mean VAS percentage decrease from baseline (62.8%, P= 0.0005), achieving the endpoint of back pain improvement >30%; the mean change was also significantly greater than the minimal clinically important difference (MCID) of a 20-point decrease (42.8,P= 0.001). This clinical improvement was maintained at Week 104. In addition, the high-dose group had clinically meaningful, statistically significant improvements in ODI and EQ-5D by 12 weeks. Clinical improvement was sustained at 26 weeks, 52 weeks, 78 weeks, and 104 weeks following a single intradiscal injection. Only the high-dose group had a significant change in disc volume, with mean increases of 249.0 mm3(P= 0.028) at 52 weeks and 402.1 mm3(P= 0.028) at 104 weeks. Overall, a minority of patients (18.3%) reported AEs that were severe, with the highest percentage being reported in the placebo group. During the course of the trial, 6.7% of patients experienced serious AEs, all occurring in the vehicle (n= 1) or placebo (n= 3) groups, none were treatment related.
"Since the inception ofDiscGenics, we have seen consistent evidence of safety and the regenerative potential of the unique disc cell population in IDCT to address disc degeneration," said Kevin T. Foley, MD, Chief Medical Officer of DiscGenics and Chairman of Semmes-Murphey Neurologic & Spine Institute. "Our early basic science studies, our demonstrated ability to safely use human cells in 14 different pre-clinical animal studies conducted in the U.S.and Japan, and recently, data from our first-in-human safety and patient-reported outcomes published in this IJSS manuscript, all support the notion that this cell has the potential to safely regenerate the intervertebral disc from the inside-out."
DDD is a chronic and progressive condition where the intervertebral disc breaks down and causes pain and disability. It accounts for nearly 40% of chronic low back pain cases in the U.S., a serious medical condition that affects 12-30% of U.S. adults at a given time and is estimated to cost the U.S. healthcare system over $100 billion each year, creating a considerable burden on the economy and individual patients.
"The significant and durable results from this study demonstrate the incredible potential ofIDCT to change the paradigm of care for patients with DDD, a condition with limited treatment options," said Flagg Flanagan, Chief Executive Officer and Chairman of the Board for DiscGenics." We are excited by the momentum the publication of these study results offers, as we expect to initiate Phase III clinical study of this novel therapy in the U.S. imminently."
AboutIDCT
IDCT (injectable disc cell therapy, orrebonuputemcel) is a standalone, single-injection biologic treatment designed to halt progression of symptomatic lumbar disc degeneration and regenerate the disc from the inside out. The active ingredient (Drug Substance) in IDCT is a live, manufactured progenitor cell population derived from donated adult human intervertebral disc tissue. These cells are enriched and expanded into Discogenic Cells through a multistep manufacturing process in a highly controlled environment under current good manufacturing practices (cGMP) that results in significant proliferation and phenotypic changes to the cells. At the completion of the manufacturing process, the Discogenic Cells are subjected to extensive testing prior to use, including identity, purity, potency, and safety evaluations. The Discogenic Cells are then mixed with a viscous Sodium Hyaluronate Solution and excipients to generate IDCT, the Final Drug Product. IDCT is cryopreserved and maintained as individual "off-the-shelf" doses for administration viapercutaneous injection into the intervertebral disc in an outpatient setting. IDCT has been granted regenerative medicine advanced therapy (RMAT)and Fast Trackdesignations by the U.S. Food and Drug Administration.
Disclaimer:IDCT is an investigational product that is under development by DiscGenics and has not been approved by the FDA or any other regulatory agency for human use.
AboutDiscGenics
DiscGenics is a privately held, late-stage clinical biopharmaceutical company developingallogeneic, cell-based regenerative therapies for musculoskeletal degeneration. It's lead product candidate, IDCT (injectable disc cell therapy, or rebonuputemcel), is a standalone, single-injection biologic treatment designed to halt progression of lumbar disc degeneration and regenerate the disc from the inside out. DiscGenics is also developing a follow-on allogeneic cell platform to enable new musculoskeletal indications. To further development of these unique therapies, and to maintain control over compliance, cost, and production timelines, DiscGenics has built and validated an in-house scalable, allogeneic cell manufacturing process and cGMP facility at its headquarters in Salt Lake City, Utah. For more information, visitdiscgenics.com.
SOURCE DISCGENICS, INC.
Read the rest here:
DiscGenics Announces the International Journal of Spine Surgery Has Published Results from an FDA-Approved Study of an Allogeneic Disc Progenitor Cell...
- Stem cells for a Webby! [Last Updated On: April 28th, 2010] [Originally Added On: April 28th, 2010]
- Stem cells for a Webby! [Last Updated On: April 28th, 2010] [Originally Added On: April 28th, 2010]
- Latest Cell Therapy Approval by FDA. Dendreon's Provenge. [Last Updated On: April 30th, 2010] [Originally Added On: April 30th, 2010]
- Latest Cell Therapy Approval by FDA. Dendreon's Provenge. [Last Updated On: April 30th, 2010] [Originally Added On: April 30th, 2010]
- Google to Invest in Regenerative Medicine [Last Updated On: May 5th, 2010] [Originally Added On: May 5th, 2010]
- Biotech tax credit appears perfectly designed for cell therapy companies to recoup research dollars spent in 2009-10 [Last Updated On: May 22nd, 2010] [Originally Added On: May 22nd, 2010]
- The changing face of PR and why it matters to regenmed [Last Updated On: June 12th, 2010] [Originally Added On: June 12th, 2010]
- The changing face of PR and why it matters to regenmed [Last Updated On: June 12th, 2010] [Originally Added On: June 12th, 2010]
- FDA files injunction again Regenerative Sciences citing Regenexx violates regulations [Last Updated On: August 12th, 2010] [Originally Added On: August 12th, 2010]
- FDA files injunction again Regenerative Sciences citing Regenexx violates regulations [Last Updated On: August 12th, 2010] [Originally Added On: August 12th, 2010]
- Careers in cell therapy & regenerative medicine [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- Careers in cell therapy & regenerative medicine [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- The LinkedIn Cell Therapy Industry Group - 1,000 members strong [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- Cell Therapies: Commercializing a New Class of Biopharmaceuticals [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- The LinkedIn Cell Therapy Industry Group - 1,000 members strong [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- Cell Therapies: Commercializing a New Class of Biopharmaceuticals [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- Hydra VII - The European Summer School on Stem Cells and Regenerative Medicine [Last Updated On: April 6th, 2011] [Originally Added On: April 6th, 2011]
- Alan Russell: Why can't we grow new body parts? [Last Updated On: May 23rd, 2011] [Originally Added On: May 23rd, 2011]
- Preserving Stem Cells: Regenerative Medicine [Last Updated On: June 7th, 2011] [Originally Added On: June 7th, 2011]
- Disease in a Dish: Using Stem Cells to Model Huntington's Disease and Spinal Muscular Atrophy [Last Updated On: June 8th, 2011] [Originally Added On: June 8th, 2011]
- Spotlight on Cancer Stem Cell Research [Last Updated On: June 21st, 2011] [Originally Added On: June 21st, 2011]
- In vivo cell trafficking just took a leap forward [Last Updated On: July 3rd, 2011] [Originally Added On: July 3rd, 2011]
- In vivo cell trafficking just took a leap forward [Last Updated On: July 3rd, 2011] [Originally Added On: July 3rd, 2011]
- A Dose of Reality on Alternative Stem Cell Treatments: What you don't know can hurt you [Last Updated On: July 7th, 2011] [Originally Added On: July 7th, 2011]
- Cell Therapy's Got Talent Technology Showcase - A Call for Cell Therapy Manufacturing Technology Presentations [Last Updated On: July 10th, 2011] [Originally Added On: July 10th, 2011]
- Cell Therapy's Got Talent Technology Showcase - A Call for Cell Therapy Manufacturing Technology Presentations [Last Updated On: July 10th, 2011] [Originally Added On: July 10th, 2011]
- Opening Remarks, Screening Stem Cells 2009: From Reprogramming to Regenerative Medicine [Last Updated On: July 22nd, 2011] [Originally Added On: July 22nd, 2011]
- Clinical trial costs [Last Updated On: July 31st, 2011] [Originally Added On: July 31st, 2011]
- Clinical trial costs [Last Updated On: July 31st, 2011] [Originally Added On: July 31st, 2011]
- A New Era in Regenerative Medicine [Last Updated On: August 1st, 2011] [Originally Added On: August 1st, 2011]
- Good Data? $100. Good Product Development? $100. Good Commercialization Strategy? Priceless. [Last Updated On: August 14th, 2011] [Originally Added On: August 14th, 2011]
- Good Data? $100. Good Product Development? $100. Good Commercialization Strategy? Priceless. [Last Updated On: August 14th, 2011] [Originally Added On: August 14th, 2011]
- You and Your Heath TV Show - Orthopedic Regenerative Medicine Part 1 [Last Updated On: August 16th, 2011] [Originally Added On: August 16th, 2011]
- The Future of Stem Cells and Regenerative Medicine [Last Updated On: August 19th, 2011] [Originally Added On: August 19th, 2011]
- Potential far-reaching implications of the ongoing fight over point-of-care autologous cell therapy [Last Updated On: September 18th, 2011] [Originally Added On: September 18th, 2011]
- Commercial-stage Cell Therapy Companies and Products [Last Updated On: September 18th, 2011] [Originally Added On: September 18th, 2011]
- Potential far-reaching implications of the ongoing fight over point-of-care autologous cell therapy [Last Updated On: September 18th, 2011] [Originally Added On: September 18th, 2011]
- Commercial-stage Cell Therapy Companies and Products [Last Updated On: September 18th, 2011] [Originally Added On: September 18th, 2011]
- Cell Therapy & Regenerative Medicine Domains Available [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- Cell Therapy & Regenerative Medicine Domains Available [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- Laurel Barchas: The World Stem Cell Summit brings people together to find therapies [Last Updated On: October 9th, 2011] [Originally Added On: October 9th, 2011]
- Regenerative Medicine - Video [Last Updated On: October 13th, 2011] [Originally Added On: October 13th, 2011]
- Commercializing Cell-based Regenerative Medicines [Last Updated On: November 13th, 2011] [Originally Added On: November 13th, 2011]
- Commercializing Cell-based Regenerative Medicines [Last Updated On: November 13th, 2011] [Originally Added On: November 13th, 2011]
- C2CAM - 2011.11.15 - Regenerative Medicine - Dulce Base - Video [Last Updated On: November 18th, 2011] [Originally Added On: November 18th, 2011]
- Dr. Craig Saunders Discusses Stem Cells and Regenerative Medicine at the Evolution of Fat Workshop - Video [Last Updated On: November 25th, 2011] [Originally Added On: November 25th, 2011]
- Sabrina Cohen Foundation Thanks Stem Cell Researchers [Last Updated On: November 27th, 2011] [Originally Added On: November 27th, 2011]
- Sabrina Cohen Foundation Thanks Stem Cell Researchers [Last Updated On: November 27th, 2011] [Originally Added On: November 27th, 2011]
- Medical tourism in Croatia - Regenerative medicine-Stem cells in reconstructive surgery - Video [Last Updated On: November 28th, 2011] [Originally Added On: November 28th, 2011]
- "You and Your Health" TV Show - Orthopedic Regenerative Medicine - Video [Last Updated On: November 28th, 2011] [Originally Added On: November 28th, 2011]
- Dr. Craig Saunders Discusses Stem Cells and Regenerative Medicine at the Evolution of Fat Workshop - Video [Last Updated On: November 28th, 2011] [Originally Added On: November 28th, 2011]
- The Future of Stem Cells and Regenerative Medicine - Video [Last Updated On: November 28th, 2011] [Originally Added On: November 28th, 2011]
- A New Era in Regenerative Medicine - Video [Last Updated On: November 29th, 2011] [Originally Added On: November 29th, 2011]
- What is Regenerative Medicine? | Los Angeles | Hollywood | Beverly Hills - Video [Last Updated On: November 29th, 2011] [Originally Added On: November 29th, 2011]
- You and Your Heath TV Show - Orthopedic Regenerative Medicine Part 1 - Video [Last Updated On: November 29th, 2011] [Originally Added On: November 29th, 2011]
- Dr Farshchian: Regenerative Medicine shows Potentials - Video [Last Updated On: December 1st, 2011] [Originally Added On: December 1st, 2011]
- An amazing story of stem cells, regenerative medicine and healing power: - Video [Last Updated On: December 1st, 2011] [Originally Added On: December 1st, 2011]
- TEDxPhoenix - Jane Maienschein - Stem Cells, Regenerative Medicine and Us - Video [Last Updated On: December 2nd, 2011] [Originally Added On: December 2nd, 2011]
- Retroviruses, Reproduction, and Regenerative Medicine: The Influence of Federal Funding - Video [Last Updated On: December 2nd, 2011] [Originally Added On: December 2nd, 2011]
- McEwen Centre for Regenerative Medicine - Video [Last Updated On: December 2nd, 2011] [Originally Added On: December 2nd, 2011]
- Mayo Clinic Regenerative Medicine Consult Service - Video [Last Updated On: December 3rd, 2011] [Originally Added On: December 3rd, 2011]
- 4th International Symposium on Regenerative Medicine, Tissue and Genetic Engineering - Video [Last Updated On: December 8th, 2011] [Originally Added On: December 8th, 2011]
- StemCellTV Talks to Elona Baum of the California Institute of Regenerative Medicine - Video [Last Updated On: December 10th, 2011] [Originally Added On: December 10th, 2011]
- StemCellTV Talks to Morrie Ruffin of Alliance for Regenerative Medicine at Meeting on the Mesa - Video [Last Updated On: December 10th, 2011] [Originally Added On: December 10th, 2011]
- StemCellTV Talks to Elona Baum of the California Institute of Regenerative Medicine - Video [Last Updated On: December 10th, 2011] [Originally Added On: December 10th, 2011]
- StemCellTV Talks to Morrie Ruffin of Alliance for Regenerative Medicine at Meeting on the Mesa - Video [Last Updated On: December 10th, 2011] [Originally Added On: December 10th, 2011]
- Active phase III or II/III cell therapy trials [Last Updated On: December 11th, 2011] [Originally Added On: December 11th, 2011]
- Active phase III or II/III cell therapy trials [Last Updated On: December 11th, 2011] [Originally Added On: December 11th, 2011]
- 2011 Summit: Harnessing Regenerative Medicine for US Service-members, Major General James K. Gilman - Video [Last Updated On: December 14th, 2011] [Originally Added On: December 14th, 2011]
- Inactive and recently failed or terminated phase III or II/III cell therapy trials [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- Recently approved cell therapy products [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- Recently approved cell therapy products [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- Inactive and recently failed or terminated phase III or II/III cell therapy trials [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- Stem Cell Clinical Trial for Heart Failure: Eduardo Marban - CIRM Spotlight on Disease - Video [Last Updated On: December 22nd, 2011] [Originally Added On: December 22nd, 2011]
- Stem Cell Clinical Trial for Heart Failure: Eduardo Marban - CIRM Spotlight on Disease - Video [Last Updated On: December 22nd, 2011] [Originally Added On: December 22nd, 2011]
- Coast To Coast AM: 15.11.2011 - Regenerative Medicine/ Dulce Base - Video [Last Updated On: December 24th, 2011] [Originally Added On: December 24th, 2011]
- Coast To Coast AM: 15.11.2011 - Regenerative Medicine/ Dulce Base - Video [Last Updated On: December 25th, 2011] [Originally Added On: December 25th, 2011]
- 2011 EMA Committee for Advanced Therapies (CAT) classification record. What can be learned? [Last Updated On: January 1st, 2012] [Originally Added On: January 1st, 2012]
- 2011 EMA Committee for Advanced Therapies (CAT) classification record. What can be learned? [Last Updated On: January 1st, 2012] [Originally Added On: January 1st, 2012]
- ACT Announces Aberdeen Royal Infirmary in Scotland as Additional Site for Phase 1/2 Clinical Trial Using hESC-Derived ... [Last Updated On: January 31st, 2012] [Originally Added On: January 31st, 2012]